Morgan Stanley Alpine Immune Sciences, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Oct 17, 2024	BUY	$17.75 - $41.6 $14 Million - $32.8 Million	789,645 New	789,645 $31.3 Million
Q1 2024 Aug 16, 2024	BUY	$17.75 - $41.6 $1.26 Million - $2.95 Million	70,904 Added 9.87%	789,645 $31.3 Million
Q1 2024 May 15, 2024	BUY	$17.75 - $41.6 $1.26 Million - $2.95 Million	70,904 Added 9.87%	789,645 $31.3 Million
Q4 2023 Aug 16, 2024	BUY	$8.54 - $20.22 $6.14 Million - $14.5 Million	718,741 New	718,741 $13.7 Million
Q4 2023 Feb 13, 2024	BUY	$8.54 - $20.22 $5.68 Million - $13.5 Million	665,268 Added 1244.12%	718,741 $13.7 Million
Q3 2023 Nov 15, 2023	BUY	$10.13 - $13.98 $33,114 - $45,700	3,269 Added 6.51%	53,473 $612,000
Q2 2023 Aug 14, 2023	BUY	$6.84 - $11.91 $152,463 - $265,473	22,290 Added 79.85%	50,204 $516,000
Q1 2023 May 15, 2023	BUY	$7.0 - $8.75 $72,471 - $90,588	10,353 Added 58.95%	27,914 $215,000
Q4 2022 Feb 14, 2023	BUY	$5.45 - $7.35 $32,694 - $44,092	5,999 Added 51.89%	17,561 $129,000
Q3 2022 Nov 14, 2022	SELL	$6.89 - $9.39 $11,278 - $15,371	-1,637 Reduced 12.4%	11,562 $84,000
Q2 2022 Oct 27, 2022	BUY	$6.71 - $9.52 $26,316 - $37,337	3,922 Added 42.28%	13,199 $112,000
Q2 2022 Aug 15, 2022	BUY	$6.71 - $9.52 $26,316 - $37,337	3,922 Added 42.28%	13,199 $112,000
Q1 2022 Oct 27, 2022	SELL	$6.41 - $13.89 $25,140 - $54,476	-3,922 Reduced 29.71%	9,277 $83,000
Q1 2022 May 13, 2022	BUY	$6.41 - $13.89 $846 - $1,833	132 Added 1.44%	9,277 $83,000
Q4 2021 Feb 14, 2022	BUY	$10.41 - $13.95 $66,738 - $89,433	6,411 Added 234.49%	9,145 $127,000
Q3 2021 Nov 15, 2021	BUY	$8.19 - $11.31 $22,391 - $30,921	2,734 New	2,734 $28,000

Others Institutions Holding ALPN

# of Institutions

Shares Held

56.2K

Call Options Held

Put Options Held

View Full List

About ALPINE IMMUNE SCIENCES, INC.

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

More about ALPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account